Back to News
Jan 13, 2026 8:10 AM

AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines

AbbVie Inc. (NYSE:ABBV) on Monday announced a voluntary agreement with the Trump administration to advance access and affordability further.

AbbVie said it will provide low prices in Medicaid while pledging $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade.

AbbVie will also expand direct-to-patient offerings through TrumpRx for medicines, including Alphagan and Combigan (for ocular hypertension), Humira (for arthritis), and Synthroid (for hypothyroidism).

The three-year agreement provides AbbVie with exemption from tariffs and future pricing mandates.

Other Deals

Last week, Johnson & Johnson ...